RN765C, a low affinity EGFR antibody drug conjugate with potent anti-tumor activity in preclinical solid tumor models

Epidermal growth factor receptor (EGFR) is a clinically validated target and often overexpressed in some solid tumors. Both EGFR tyrosine kinase inhibitors and ligand-blocking antibodies have been approved for treatment of NSCLC, head and neck cancers and colorectal cancers. However, clinical respon...

Descripción completa

Detalles Bibliográficos
Autores principales: Wong, Oi Kwan, Tran, Thomas-Toan, Ho, Wei-Hsien, Casas, Meritxell Galindo, Au, Melinda, Bateman, Marjorie, Lindquist, Kevin C., Rajpal, Arvind, Shelton, David L., Strop, Pavel, Liu, Shu-Hui
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2018
Materias:
Priority Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6173368/
https://www.ncbi.nlm.nih.gov/pubmed/30323890
http://dx.doi.org/10.18632/oncotarget.26002

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6173368/
https://www.ncbi.nlm.nih.gov/pubmed/30323890
http://dx.doi.org/10.18632/oncotarget.26002

Ejemplares similares